Clinical Laserthermia Systems AB (CLS) has signed a commercial collaboration agreement with Exact Imaging Inc.
The two companies will jointly develop and market a product for high-resolution micro-ultrasound-guided focused laser ablation (FLA).
Based in Sweden, Clinical Laserthermia develops therapies, systems and single-use instruments for the treatment of cancer, while Exact Imaging is a Canadian medical device company that developed the ExactVu™ micro-ultrasound device.
US-based Parachute Health LLC has raised $15m through a series B financing round led by Insight Venture Partners.
Greater New York Hospital Association Ventures, Loeb Holding Corp, and former McKesson Extended Care president Fred Browne also participated in the funding round.
The company plans to use the funds to expand its medical equipment and services to other markets in the US.
CMR Surgical Ltd has raised $100m through a series B financing round led by Zhejiang Silk Road Fund.
Existing investors Escala Capital Investments, LGT, Cambridge Innovation Capital, and Watrium also participated in the funding round.
The funds are intended to be used for the commercialisation of the company’s Versius system.
Based in the UK, CMR Surgical is a designer and developer of the next-generation surgical robotic system.
TRiCares SAS has raised €22m ($25.6m) through a series B funding round led by Wellington Partners Venture Capital, Andera Partners, and BioMedPartners.
Existing investors, including CMC CIC Innovation, CapDecisif Management, and Go Capital, also participated in the funding round.
Based in France, TRiCares is focused on the development of a catheter-based valve replacement system for the treatment of tricuspid valve regurgitation.
The company plans to use the funds for product development and clinical trials, and to obtain European CE registration.
Genetesis LLC has raised $7.5m through a series A financing round led by CincyTech.
The funding round included participation from Radical Investments LP, Ohio Innovation Fund, and Raptor Group Holdings LP.
Based in the US, Genetesis is a developer of medical imaging devices.
The funds will be used towards clinical trials, commercial launch activities, and installation of additional CardioFlux™ systems.
MDxHealth SA has signed a worldwide licensing agreement for the rights to manufacture and sell Koninklijke Philips NV’s recently validated prognostic biomarker for the treatment of prostate cancer.
The biomarker, known as phosphodiesterase-4D7 (PDE4D7), will be used as a prognostic test.
Based in Belgium, MDxHealth is a medical device company that specialises in the development of next-generation epigenetic prostate cancer tests, while Koninklijke Philips is a Dutch medical device company.
The agreement will help MDxHealth to prepare for the launch of its prostate cancer test kit, InformMDx.